|
Subsequent Events
|
12 Months Ended |
|---|---|
|
Dec. 31, 2014
|
|
| Subsequent Events | |
| Subsequent Events |
13. Subsequent Events In March 2015, Actavis and the Company signed a letter agreement wherein Actavis agreed to pay the Company $10.0 million to fund the expansion of the Company's ongoing Phase 2b trial of TRV027 from 500 patients to 620 patients. The March 2015 letter agreement does not otherwise amend the terms of the May 2013 option agreement described in Note 10 above.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. No definition available.
|